Kura Oncology, which is developing protein inhibitor therapies for solid tumors and blood cancers, announced terms for its IPO on Wednesday.
The La Jolla, CA-based company plans to raise $60 million, which would equate to an offering of 3.75 million shares at its current price of $16 on the OTCQB (symbol: KURO). At the proposed price, Kura Oncology would command a fully diluted market value of $359 million. The company filed for an $86 million IPO on October 20.
Kura Oncology, which was formed in August 2014, plans to list on the Nasdaq under the symbol KURA. Citi and Leerink Partners are the joint bookrunners on the deal. It is expected to price during the week of November 2, 2015.
